ProfileGDS5678 / 1419492_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 46% 48% 47% 70% 47% 46% 46% 47% 75% 46% 47% 47% 46% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1348746
GSM967853U87-EV human glioblastoma xenograft - Control 23.1188748
GSM967854U87-EV human glioblastoma xenograft - Control 33.1150547
GSM967855U87-EV human glioblastoma xenograft - Control 44.4015670
GSM967856U87-EV human glioblastoma xenograft - Control 53.0526947
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1669246
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1377446
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0905647
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9595975
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0644346
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0993947
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.080747
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1010146
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3867555